Eli Lilly and Company Overview
Get informed when a big investor buys or sells
+ Follow81.82%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, LLY.SW shows a ROE of 81.82%. That is above the Healthcare sector average of -75.84%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about -75.84%. Eli Lilly and Company is at 81.82%, which is higher that average. That is roughly 207.9% above the sector mean. Use the comparison chart on this page to see how LLY.SW stacks up against individual peers as well.
Check the historical chart to see whether LLY.SW's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Eli Lilly and Company with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Eli Lilly and Company's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 81.82%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about -75.84%, while LLY.SW is at 81.82%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
